Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2008 Jul 11;1(1):11.
doi: 10.1186/1755-7682-1-11.

Plasmatic Level of Neurosin Predicts Outcome of Mild Cognitive Impairment

Free PMC article

Plasmatic Level of Neurosin Predicts Outcome of Mild Cognitive Impairment

Manuel Menendez-Gonzalez et al. Int Arch Med. .
Free PMC article


Background: Mild Cognitive Impairment (MCI) is a disorder considered to be a transitional stage from health to dementia. Diagnosis of dementias at these early stages is always troublesome because the pathophysiologic events leading to dementia precede clinical symptoms. Thus, the development of biomarkers that can be used to support the diagnosis of dementias at early stages is rapidly becoming a high priority. We have recently reported the value of measuring plasmatic levels of neurosin in the diagnosis of Alzheimer's disease (AD). The aim of this study is to determine whether measuring plasmatic concentration of neurosin is a valuable test to predict progression of MCI.

Methods: Plasmatic neurosin concentrations were measured in 68 MCI patients and 70 controls subjects. Blood samples were obtained at the beginning of the study. Sixty six patients diagnosed with MCI were observed for 18 months. In 36 patients a second blood sample was obtained at the endpoint.

Results: The mean value of plasmatic neurosin concentration differs significantly between MCI patients who converted to Dementia with vascular component, those who converted to AD, or those who remained at MCI stage. The relative risk of developing Dementia with vascular component when neurosin levels are higher than 5.25 ng/ml is 13 while the relative risk of developing mild AD when neurosin levels are lower than 5.25 ng/ml is 2. Increases in the levels of neurosin indicate progression to Dementia with vascular component.

Conclusion: The measurement of plasmatic neurosin level in patients diagnosed with MCI may predict conversion from MCI to Dementia with vascular component. A single measurement is also valuable to estimate the risk of developing AD and Dementia with vascular component. Finally, repeated measurement of plasmatic neurosin might be a useful test to predict outcome in patients with MCI.


Figure 1
Figure 1
Differences in plasmatic level of neurosin between the three diagnostic groups after follow up. The plasmatic neurosin concentration is shown for the three final diagnostic groups (MCI in green, AD in blue and Dementia with vascular component in brown). Statistical differences were found between Dementia with vascular component and both AD and MCI.
Figure 2
Figure 2
Evolution with time of the plasmatic level of neurosin. Colour legend shows diagnostic groups after follow up. Vertical bars show standard deviation at baseline and final (after 18 months) points.

Similar articles

See all similar articles

Cited by 3 articles


    1. Ferri CP, Prince M, Brayne C, Brodaty H, Fratiglioni L, Ganguli M, Hall K, Hasegawa K, Hendrie H, Huang Y, Jorm A, Mathers C, Menezes PR, Rimmer E, Scazufca M. Alzheimer's Disease International. Global prevalence of dementia: a Delphi consensus study. Lancet. 2005;366:2112–7. doi: 10.1016/S0140-6736(05)67889-0. - DOI - PMC - PubMed
    1. Storandt M, Grant EA, Miller JP, Morris JC. Longitudinal course and neuropathologic outcomes in original vs revised MCI and in pre-MCI. Neurology. 2006;67:467–73. doi: 10.1212/01.wnl.0000228231.26111.6e. - DOI - PubMed
    1. Petraki CD, Karavana VN, Skoufogiannis PT, Little SP, Howarth DJ, Yousef GM, Diamandis EP. The spectrum of human kallikrein 6 (zyme/protease M/neurosin) expression in human tissues as assessed by immunohistochemistry. J Histochem Cytochem. 2001;49:1431–41. - PubMed
    1. Okui A, Kominami K, Uemura H, Mitsui S, Yamaguchi N. Characterization of a brain-related serine protease, neurosin (human kaillikrein 6), in human cerebrospinal fluid. Neuroreport. 12:1345–50. doi: 10.1097/00001756-200105250-00011. 2001 May 25, - DOI - PubMed
    1. Yousef GM, Luo LY, Scherer SW, Sotiropoulou G, Diamandis EP. Molecular characterization of zyme/protease M/neurosin (PRSS9), a hormonally regulated kallikrein-like serine protease. Genomics. 1999;62:251–9. doi: 10.1006/geno.1999.6012. - DOI - PubMed

LinkOut - more resources